Association between Copeptin and Metabolic Syndrome: A Systematic Review.

ABSTRACT:

Background

Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS.

Methods

We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. The risk of bias was evaluated with the Newcastle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values.

Results

A total of 7 studies (5 cross-sectional, 1 case-contro

SUBMITTER: Rojas-Humpire R 

PROVIDER: S-EPMC9617695 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature